Providers

“Unfortunately, limited access to these therapies worldwide appears to be a major challenge,” the researchers wrote.

An observational registry study revealed that inflammatory disease activity is not the only factor influencing the achievement of treatment targets for patients with rheumatoid arthritis (RA).

An in-depth look into what the drug is being used for and what has contributed to the shortage.

Mark A. Socinski, MD, executive director at AdventHealth Cancer Institute, discussed the emergence of targeted therapies for lung cancer and their ongoing impact on outcomes for certain patients.

Jun Gong, MD, of Cedars-Sinai Medical Center, discusses the latest data on adagrasib in colorectal cancer, the importance of conducting genomic testing, and more.

A one-size-fits-all approach to alternative payment models (APMs) often isn’t very fair to community practices, said Miriam Atkins, MD, FACP, president of the Community Oncology Alliance.

Coverage from The US Oncology Network Payer Transformation Summit, held September 27-29, 2023, in Atlanta, Georgia.

Real-world data presented at the 2023 American Society of Hematology Annual Meeting and Exposition showed similar toxicity profiles and outcomes among older and younger patients with multiple myeloma (MM) treated with teclistamab.

A single-center, observational study conducted in the Czech Republic investigated the determining factors in delayed diagnoses in multiple sclerosis (MS) and how these delays impact patient outcomes.

The most-read content from the 2023 American Society of Hematology Annual Meeting and Exposition included the latest in treating hematologic malignancies, the hope brought by novel therapy strategies, and the potential for artificial intelligence to improve diagnostic accuracy.

Our top multiple myeloma (MM) content this year included research suggesting many patients still face poor prognoses despite advances, a case study of unique MM presentation, and research presented at the 2022 American Society of Hematology Annual Meeting.

This year’s most-read articles on inflammation explored predictive biomarkers, medication acceptance, the impacts of long COVID-19, and more.

In the phase 3 EV-302/KEYNOTE-A39 clinical trial, the antibody-drug conjugate enfortumab vedotin plus PD-1 inhibitor pembrolizumab nearly doubled both median overall survival and progression-free survival compared with chemotherapy.

In 2023, adalimumab biosimilars took center stage in the biosimilar space due to 8 long-anticipated products finally launching.

The Center on Health Equity and Access offers updates on recent news, breakthroughs in research, and ongoing initiatives aimed at tackling health care disparities and enhancing overall access to top-notch care.

Following the FDA approval of vonoprazan in the treatment of erosive esophagitis, Dr Colin Howden discussed important information about the new therapy.

This year’s most-read spinal muscular atrophy(SMA) articles explored mental health, new technologies, caregiver well-being, and more.

The bipartisan bill would help lower Medicare costs and improve quality of care, according to the National Association of ACOs.

This year’s most-read articles on autoimmune diseases explored comorbidities with cardiovascular disease, the value of new forms of monitoring and therapy, and more.

Colin Howden, MD, discusses the mechanisms at work in vonoprazan as well as patient monitoring and potential future uses following a recent FDA approval for the treatment of erosive esophagitis.

This year’s most-read articles on multiple sclerosis (MS) explored the emergence of new medications, modes of therapy, and predictive tools in the study of MS.

A late-breaking abstract presented at the American Society of Hematology Annual Meeting and Exposition supports the addition of subcutaneous daratumumab to standard-of-care bortezomib, lenalidomide, and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation.

Adding metformin to the insulin regimen for pregnant patients with preexisting type 2 diabetes (T2D) or gestational diabetes diagnosed early in pregnancy did not reduce the risk of neonatal adverse outcomes.

A trial comparing baricitinib against placebo in people with new-onset type 1 diabetes suggests use could contribute to the preservation of β-cell function.

Mona Shahriari, MD, assistant clinical professor of dermatology at Yale University and associate director of clinical trials at Central Connecticut Dermatology, discusses how dermatologists and clinicians can work towards increasing diversity and inclusion in treating patients with skin of color with plaque psoriasis.